Contact 2: Illinois Supreme Court docket ruling might put a refund in owners’ pockets

JEFFERSON CITY, Missouri – Some Missouri senators want the Department of Social Services to block abortion providers from Medicaid funding for unethical behavior.

Following a special summer session to renew the Federal Reimbursement Allowance (FRA), the tax paid by health care providers that fund Missouri’s Medicaid program, Senate Chairs formed a committee to address concerns about the Medicaid funding going to abortion providers to dispel, such as Planned Parenthood.

The Senate Interim Committee on Medicaid Accountability and Taxpayer Protection met for the third time on Thursday since July. The focus of the hearing was on discussing a committee report making changes to the state’s Medicaid system. Senator Bill White, R-Joplin, chairs the committee and has read the six-page report.

“The state has the authority to establish qualification standards for Medicaid providers in Medicaid programs and to take action against providers who do not meet these standards,” White said.

One of the proposals would enable joint investigations against Medicaid providers under the Department of Social Services (DSS) and the Department of Health and Senior Services (DHSS). This regulatory proposal would have to be approved by the members of the committee and then sent to the department.

“The committee urges the DSS and DHSS to work together on amending and expanding the existing rules to include the DSS’s compliance with all state laws,” said White.

These violations of state law include failure to comply with patient consent, failure to keep medical records, failure to cooperate with DHSS during an examination, failure to ensure adequate facilities and sterilized equipment, and failure to provide the women named with necessary printed matter Materials to make available to an extra-state abortion facility. “

White and other members asked the DSS and DHSS to draft emergency rules and put them into effect as soon as possible. As part of this change, DSS might consider revoking or denying a license based on DHSS reports.

Senator Lauren Arthur, D-Kansas City, is concerned the language may affect more healthcare providers than intended.

“If this is a back door attempt to invalidate Planned Parenthood, I am concerned about the impact it would have on access to health care,” said Arthur. “There doesn’t seem to be a solution for those who would feel this loophole.”

Senator Jill Schupp, D-Creve Couer, told the committee she feared the investigation could create a gap in health care for Missourians.

“I am concerned about what we are pushing forward and trying to move forward quickly, in a process that may withhold the necessary health care from our recipients,” said Schupp.

“I’m not sure how this will benefit the state or the beneficiary. I think this is intended to allow DSS more control without having to conduct its own investigation.”

A proposed legislative change in the report allows the state to deny or revoke Medicaid funding to MO HealthNet providers, such as abortion facilities, which in Missouri are just planned parenting, for unethical behavior.

“That Missouri has an interest in protecting unborn children during pregnancy and in ensuring respect for all human life from conception to natural death,” said White.

This change in the law would require the approval of the General Assembly when members return in January. Arthur said she couldn’t support the language because she feared it could hurt Medicaid funding across the state.

“Until there is assurance that we are complying, I believe we are taking a risk that I am not comfortable with,” said Arthur.

Planned Parenthood is already banned from using Medicaid funds for abortions. Another important part of the proposal means Missouri could force the closure of the Central West End site in St. Louis if an abortion facility like Planned Parenthood in another state fails to comply.

White said members are expected to sign the report in the coming days, with the report being sent to departments early next week.

The committee will meet again on October 4 to hear from MO Healthnet on transparency issues.

Bragar Eagel & Squire, P.C. is Investigating Tencent Music Leisure Group on Behalf of Tencent Stockholders and Encourages Buyers to Contact the Agency

TipRanks

Wells Fargo: 2 Strong Stocks With Upward Potential Above 70%

Wells Fargo analysts have scrutinized the market, or specifically the winners and losers of current market conditions. In a recent release, senior equity analyst Chris Harvey writes, “The risk and outperformance of small caps have made this stock market a haven for stock pickers.” Obviously, Harvey sees that small-cap stocks are doing well right now and are doing well for investors numerous options are available to choose from. While small caps are generally a riskier investment, one distinct advantage over bigger names is the potential for higher returns. This is where the risk / reward paradigm comes into play. Following Harvey’s tip, the company has made a number of recommendations and found small-cap stocks on the cusp of growth that promise a return of 70% or more for the coming year. We ran two of them through the TipRanks database to see what other Wall Street analysts were up to. Ping Identity Holding (PING) Based on the technology industry, Wells Fargo’s first pick is Ping Identity Holding Corp, which specializes in identity management. The company offers a range of products that customers can use to control login and access to networks and databases. While Ping Identity has been in business for nearly 20 years, it has only been a public company for a year and a half. In the company’s most recent quarterly report for the fourth quarter of 2010, Ping reported mixed results, and immediately posted a 20% decline in price. The EPS was a net loss of 4 cents per share. Revenue was down 7% year-over-year to $ 63.2 million, but increased 5.5% sequentially, marking the second highest quarterly revenue the company has had since going public. For the full year, total revenue was $ 243.6 million, driven by a 15% increase in annual recurring revenue (ARR) year over year, which hit $ 259.1 million. The company saw a 34% increase in customers with an ARR of more than $ 1 million, a solid win on one key metric. Wells Fargo analyst Philip Winslow was particularly impressed with the ARR gain. “Ping reported solid fourth quarter results, with ARR exceeding expectations. The 15% year-over-year ARR growth was above consensus estimates of $ 256.1 million due to continued adoption of SaaS solutions, which accelerated more than expected and accounted for + 15% of total ARR, ” wrote the 5-star analyst. Winslow added, “The company is seeing continued signs of pent-up demand as customers phased out their purchases as projects previously suspended from COVID budget pressures emerge in the pipeline and companies modernize legacy systems whose flaws are exposed been the past year. “To this end, Winslow rates PING as overweight (i.e. buy) and has a target price of $ 40, indicating upside potential of 76% over the next 12 months. (To see Winslow’s track record, click here.) Winslow is not an outlier in his bullish stance, but there is some divide on Wall Street over ping. The analysts’ consensus view is a moderate buy based on a dozen ratings that consisted of 7 buys and 5 holds The shares are priced at $ 22.59 and their average target price of $ 33.71 indicates a year-long share Upward movement of 49%. (See PING stock analysis on TipRanks.) Sangamo Therapeutics (SGMO) Let’s shift gears and take a look at the life science sector. Sangamo is a biotechnology company focused on developing genomic therapies to treat genetic diseases. The company’s pipeline includes 17 different programs at various stages of development that target a range of diseases, including IBD, beta thalassemia, sickle cell disease and hemophilia A. Back in December, the company reported an update on its ongoing collaboration with Pfizer on Giroctocogene fitelparvovec. This is a gene therapy product that is being developed to treat haemophilia A. Follow-up data from the Phase 1/2 Alta study indicated that the drug was well tolerated and safe in the small cohort of patients tested. Giroctocogene fitelparvovec is now starting the patient dosage phase of the phase 3 AFFINE study. In February, Sangamo reported that it had entered into a global partnership with Biogen to develop and commercialize new therapies for gene regulation. The therapies under consideration target Alzheimer’s, Parkinson’s and other neurological diseases. The bulls include Wells Fargo analyst Yanan Zhu, who wrote of the bigger picture: “Overall, we continue to see significant upside in the company’s genomic drug pipeline programs and platforms, particularly the regulatory T (Treg) cell therapy platform may target a wide range of autoimmune diseases and the ZFP-TF gene regulatory platform, which may target certain difficult-to-target neurological indications… ”In light of these comments, Zhu reiterates the company’s overweight (i.e. buy) rating on the stock and set up target price $ 29, suggesting a robust upward move of 158%. (To see Zhu’s track record, click here.) Overall, SGMO has shown optimism and caution about the consensus view among sell-side analysts. Out of 5 analysts surveyed over the past 3 months, 2 are bullish about the stock while 3 continue to fail. The bulls have the edge, however, as the average price target is $ 19.40 and indicates a 72% uptrend. (See SGMO stock analysis on TipRanks.) To find great ideas for trading stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, ‘a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

Did You Lose Cash on Your Funding? Contact Johnson Fistel Relating to Investigation

Bloomberg

Dealer arrested as WallStreetBets phenomenon hits Japan

(Bloomberg) – An individual investor buys shares in a small business, promotes their position on social media, and inspires a horde of followers to do the same. The share price goes to the moon – before falling back to earth. It’s an all-too-familiar story to anyone watching the market in 2021, but this wasn’t GameStop Corp. It wasn’t even in America. And it happened in 2018. It was in the Japanese city of Osaka that a day trader known by the nickname Tonpin hit a tiny precision tool and mold maker called Nichidai Corp. and posted this on Twitter, where he has more than 55,000 followers. The stock rose more than six-fold in the first three months of 2018 before losing most of its profits. The person behind the nickname was Toru Yamada, a former money manager, and he and another man were just arrested for market manipulation, according to Japanese media reports. He was arrested not for bringing up the stock on Twitter, but rather on suspicion of keeping the stock price low – although that would have lifted restrictions on margin trading, causing stocks to hit new highs in the incident shows how regulators sift through unusual trading patterns and often come to conclusions years later. This could pique the interest of protagonists and observers of the recent meme stock rally in the US, such as users of the Reddit forum WallStreetBets.Yamada, which has not yet been charged and it is not clear whether it will. And while no one is suggesting that U.S. traders use tactics similar to the ones they allegedly used, the case shows the risks that can be involved in becoming a high profile social media investor. While you’re in the public spotlight, you may also be caught in the crosshairs of regulators: “Everyone will be on their toes,” said Taketsugu Agari, the investor known as Takezo on Twitter, where he has nearly 100,000 followers. “People don’t know what’s right and what’s wrong,” he said. “People don’t know the rules.” Calls and direct Twitter messages to Yamada went unanswered. The Osaka District Procuratorate declined to comment. The Securities and Exchange Surveillance Commission, Japan’s market observer, was not immediately available for comment. According to local media reports, the prosecution did not make it clear whether the men had approved or denied the charges. A regulatory filing shows that Yamada’s first disclosed purchase of Nichidai shares was on December 8, 2017 and he was gradually increasing his stake. When he first tweeted about it on February 1 of the next year, stocks had nearly tripled. In March of this year, Yamada and another man placed a large number of sell orders below market price reports shortly before the close of trading, according to media reports. Their intent was to keep the stock price below a certain level to ensure that restrictions on new margin trading on the stock were lifted, the reports said. The stock was exempt from the measures and rose up to 18% on March 12 on its next trade. In a tweet on March 10, Yamada appeared to be discussing this process, showing screenshots of Nichidai trades just before the close of trading, although this is unclear aside from his arrest, Yamada has had a lot of arguments on Twitter over the years over his discussions about his investments. “The authorities need to put some regulations in place,” said Soichiro Iwamoto, a longtime trader whose company gives new advice to investors, said in an interview about the practice of talking stocks on social media. “The investors here don’t have enough financial knowledge.” Others wondered what exactly Yamada had done wrong. “It is amazing that selling to lift margin restrictions is being treated as market manipulation,” Akira Katayama, a busy day trader named Gogatsu, wrote after his arrest. Japanese retail investors have advocated the country’s thousands of thinly traded stocks online for more than a decade, starting with the bulletin boards popular in the mid to late 2000s before moving to Twitter, the dominant platform in recent years. Locust Lords “are known to attract a swarm of day traders. Yamada was the last of the Lords to fall silent in June when he said he was taking a break from Twitter after his account was briefly suspended. Okansanman, an anonymous account with 175,000+ followers and known for its quick delivery of Breaking News, went dark in early 2019 and has not re-emerged. Mysterious Twitter user Drawing a Swarm of Japan TradersYamada worked for two Chinese state funds before starting day trading in Japan in 2013, he told Bloomberg News last year. He shared the opinion on Twitter even before his arrest with devoted followers who copied his deals and others who accused him of being a manipulator, and used his influence to pump up stocks before they were dumped. “When a lot of Japanese lose, they want to blame it on someone else,” he said last year, wiping off his critics. Followers may have to wait to learn of Yamada’s fate. Under Japanese law, he can be held for up to 23 days before charges are brought. Meanwhile, many of his colleagues in the country who enjoy discussing stocks are moving from Twitter to other places, including encrypted messaging apps like Line and new platforms like Clubhouse, according to investor Agari. That makes it harder for regulators to monitor, he said. Read More: GameStop Frenzy Is Lost In Translation For Japan’s Day Dealers. If the Japanese experience matters, regulatory action may be a long time coming, if it happens at all. “This has been so for over a decade, since people have used bulletin boards,” Agari said, referring to retail investors talking about stocks online. “America is starting to look like Japan.” (Updates with more details) For more articles like this, visit bloomberg.com. Sign up now to keep up with the most trusted business news source. © 2021 Bloomberg LP

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Invitations GameStop Corp. (GME), AMC Leisure Holdings, Inc. (AMC) and BlackBerry Ltd. (BB) Buyers to Contact its Attorneys, Agency Investigating On-line Brokerages’ Market Manipulation Scheme

TipRanks

Those 2 penny stocks could rally as much as $ 11, analysts say

At its FOMC meeting in January, the Federal Reserve held rates stable – they are currently near their lows, and unsurprisingly, the Fed is holding them there. Fed chairman Jerome Powell may have fed some market pessimism when speaking after the meeting, pointing out that unemployment has risen in recent months. For market watchers seeking support, there is consolation in the Fed’s monetary policy. The central bank has pledged to buy $ 80 billion worth of Treasury bills every month and has put a rate hike on hold until 2023. At least one top strategist sees the current market environment in terms of opportunities. JPMorgan strategist Marko Kolanovic takes an optimistic stance and writes: “We assume that the global COVID pandemic will decline rapidly in the coming weeks. In fact, the pace of decline in new cases in the past two weeks is the fastest ever in the US and worldwide. Central banks should remain accommodative amid rising unemployment and over a decade of low inflation that is below their targets – term turmoil like this week offers an opportunity to switch from bonds to stocks. “With that outlook in mind, we set out to find exciting opportunities that won’t break the bank, namely penny stocks. Priced at $ 5 or less, these stocks offer investors the highest growth potential available in the market. Again, there is a risk, as the “pennies” are often cheap for a reason. Careful examination is therefore essential. Using TipRanks’ database, we identified two penny stocks that received a consensus rating of “Strong Buy” from the analyst community. Not to mention, every company has huge upside potential as some analysts see it spike to $ 11. BioLineRx, Ltd. (BLRX) We’re starting BioLineRx, a clinical-stage biopharmaceutical company focused on developing new cancer treatments. Oncology is an important area for state-of-the-art biopharmaceuticals. Cancer is often fatal and often resistant to topical treatments – and these treatments themselves often cause severe side effects in patients. BioLineRx has an active pipeline of drug candidates. The most advanced, however, is motixafortid, a synthetic peptide that has completed patient enrollment in a phase 3 study to mobilize stem cells for autologous bone marrow transplantation. The drug is being studied for effectiveness in promoting bone marrow harvesting prior to cancer treatment. The results of a pre-planned interim analysis showed “statistically significant evidence for motixafortid treatment at the primary endpoint” so significant that enrollment was completed early with 122 patients instead of 177. Mobilizing stem cells using Motixafortid is believed to be the company’s most efficient route to registering the new drug for regulatory approval. Given the potential of Motixafortide and its share price of $ 2.40, some analysts believe now is the time to pull the trigger. Mark Breidenbach, 5-star analyst, reported on BLRX for Oppenheimer: “Our thesis continues to focus on motixafortid in the mobilization of stem cells, and we see a separation between the company’s market capitalization and the market opportunity of Motixafortid as a stem cell mobilizer. The key GENESIS secondary endpoints are expected by mid-2021 and we see little risk for this data … “The analyst added,” We believe the results of the Phase 3 GENESIS trial will prompt the majority of transplant doctors might choose to combine BL-8040 with G-CSF instead of Mozobil if the drug is approved. In addition to our work, BL-8040 contains for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company has a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck and Genentech. “With all of this in mind, Breidenbach rates BLRX as a buy, and its target price of $ 11 points to an uptrend of a whopping 358% for the coming year. (To see Breidenbach’s track record, click here.) The rest of the street seems to reflect Breidenbach’s bullish sentiment. With 3 buys and no holds or sells, the consensus is unanimous: BLRX is a strong buy. On top of the good news, the upside is ~ 428% based on the average price target of $ 12.67. (See BLRX stock analysis on TipRanks) Kindred Biosciences (KIN) While most biotech companies focus on human drugs, we’re not the only market. Kindred Biosciences is a biopharmaceutical company in the veterinary marketplace developing biological medicines to improve the lives of our pets and work animals. The company describes its mission as'[bringing] Pet the same safe and effective medications that human family members enjoy. Parvovirus (CPV) is a highly infectious and fatal viral disease that affects dogs. While vaccines are available, untreated cases can have a mortality rate of over 91%. Kindred’s lead drug in the pipeline, KIND-030, is currently in development for the treatment of this disease. The drug candidate is currently pursuing two paths in the development process – one for the treatment of established infections and one for the prophylactic preventive treatment of CPV. The prophylactic study showed positive results, with all dogs treated avoiding infection while all dogs in the placebo group developed parvovirus disease. KIND-030 also showed a mortality benefit when given to treat infections. The drug candidate is in the crucial study phase of development, the last before possible approval. Last month, Kindred announced it had entered into an agreement with Elanco Animal Health, a major veterinary drug company, to manufacture KIND-030. Cantor analyst Brandon Folkes sees a lot of potential in Kindred, especially in the company’s agreement with Elanco. “A partnership with a leading animal health company, in this case Elanco, is exactly what the company needs from our point of view. This confirms, in our view, KIN’s new strategic approach as a drug developer to find larger trading partners. We believe today’s deal should show investors that Kindred’s pipeline continues to have significant value that could be realized in the next 12 to 18 months, ”said Folkes. Kindred is also conducting studies with tirnovetmab, or KIND-016, an antibody directed against IL31, for the treatment of atopic dermatitis in dogs. The pivotal efficacy study of this drug began in the final quarter of 2020. There is a potentially huge market for successful dermatitis treatment in dogs. Over the past six years, there has been a 47% increase in veterinary visits for dogs with severely itchy skin and the market is valued at $ 900 million or more. “While 2020 was a tough year for KIN stock, the company continued to take several shots on goal from its diversified pipeline that could reward investors at current levels. With multiple readings in 2021 and once again focusing solely on developing its pipeline, we anticipate that 2021 could be a banner year for KIN should it be able to deliver on the promise of its pipeline and, in particular, its atopic dermatitis portfolio, ” so the analyst summarized. To do this, Folkes gives KIN a price target of $ 11, which means an upside of 139% in 2021 and an overweight (i.e. buy). (To see Folkes’ track record, click here.) Kindred is another company with a unanimous consensus from Strong Buy analysts based on 5 recent Buy ratings. The stock has an average price target of $ 10.25, indicating ~ 124% growth from the current trading price of $ 4.59. (See KIN Stock Analysis on TipRanks.) To find great ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.